Stock Events

Stock Events

Adicet Bio 

$9.59
56
+$0.16+1.7% 20:00 Today
+$0.00+0%23:30After hours

Statistics

Day High
9.71
Day Low
9.57
52W High
17.44
52W Low
6.01
Volume
2,089
Avg. Volume
-
Mkt Cap
89.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.64
-3.19
-1.75
-0.3
Expected EPS
-1.588376
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-116.8MNet Income

Analyst Ratings

45.33Average Price Target
The highest estimate is 90.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACET. It's not an investment recommendation.
Amazon
7
AMZN
Pfizer
7
PFE
Ares Capital
7
ARCC
Apple
6
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, similar to Adicet Bio's focus on cell therapies for cancer, making them direct competitors in the cell therapy space.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics operates in the field of allogeneic CAR T cell therapies, directly competing with Adicet Bio's allogeneic cell therapy approach for treating cancer.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing and CAR-T therapy developments, competing in the innovative therapy space including cancer treatments, overlapping with Adicet Bio's focus areas.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a strong presence in the cell therapy market, including Kymriah, a CAR-T therapy for cancer, making it a competitor to Adicet Bio.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T therapy for cancer, directly competing with Adicet Bio's cell therapy approaches.
Precigen
PGEN
Mkt Cap2.49B
Precigen is a biotechnology company that develops gene and cell therapies, including CAR-T therapies for cancer, making it a competitor in the same field as Adicet Bio.

About

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Show more...
CEO
Chen Schor
Employees
102
Country
United States
ISIN
US0070022076
WKN
000A41X5V

Listings

STU
DE
1IJ.STU
F
DE
1IJ.F
MU
DE
1IJ.MU
LSE
GB
0HX7.LSE

0 Comments

Share your thoughts

FAQ

What is Adicet Bio stock price today?▼
The current price of ACET is $9.59 USD — it has increased by +1.7% in the past 24 hours. Watch Adicet Bio stock price performance more closely on the chart.
What is Adicet Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adicet Bio stocks are traded under the ticker ACET.
Is Adicet Bio stock price growing?▼
ACET stock has risen by +5.85% compared to the previous week, the month change is a +4.13% rise, over the last year Adicet Bio has showed a -15.96% decrease.
What is Adicet Bio market cap?▼
Today Adicet Bio has the market capitalization of 89.78M
When is the next Adicet Bio earnings date?▼
Adicet Bio is going to release the next earnings report on November 11, 2026.
What were Adicet Bio earnings last quarter?▼
ACET earnings for the last quarter are -1.99 USD per share, whereas the estimation was -1.69 USD resulting in a -17.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adicet Bio revenue for the last year?▼
Adicet Bio revenue for the last year amounts to 0 USD.
What is Adicet Bio net income for the last year?▼
ACET net income for the last year is -116.8M USD.
How many employees does Adicet Bio have?▼
As of September 04, 2026, the company has 102 employees.
In which sector is Adicet Bio located?▼
Adicet Bio operates in the Health & Wellness sector.
When did Adicet Bio complete a stock split?▼
The last stock split for Adicet Bio was on December 30, 2025 with a ratio of 1:16.
Where is Adicet Bio headquartered?▼
Adicet Bio is headquartered in BOSTON, United States.